-
Mashup Score: 0
Read the full article here
Tweet
Cardiac Failure With Robert J. Mentz, MD, and Anuradha Lala, MD
CardiologyDrs. Robert J. Mentz, MD, and Anuradha Lala, MD, are world-renowned cardiologists and Co-Editors in Chief of JCF. Dr. Robert Mentz is an Associate Professor of Medicine and Chief of the Heart Failure Section at Duke University while Dr. Lala is an Associate Professor of Medicine at the Zena & Michael A Wiener Cardiovascular Institute and in the Department of Population Health Science and Statistics at Icahn School of Mount Sinai and Mount Sinai Hospital.
-
Mashup Score: 0
Read the full article here
Tweet-
RESULTS: Spironolactone may reduce the risk of new or worsening heart failure (HF); however, it did not significantly impact the rate of death, new heart attack, or stroke.
-
-
Mashup Score: 0
Read the full article here
Tweet-
RESULTS: In patients with hereditary or wild-type transthyretin amyloidosis with cardiomyopathy (ATTR-CM), a single dose of nexiguran ziclumeran was well-tolerated and associated with consistent deep, rapid, and durable reductions in serum transthyretin (TTR) accompanied by evidence of limited disease progression.
-
RESULTS: Pharmacists in the AF/AF+ groups averaged 1.2 more HF-related encounters per month compared to the education only group (p<0.01) and 0.2 more HF medication adjustment encounters per month (p=0.01). AF/AF+ groups also showed a higher rate of new or increased mineralocorticoid receptor antagonist (MRA) prescriptions (11.6% vs. 9.2%, p<0.01).